Last updated:
Author(s):
Charli E. Harlow, Emeka Uzochukwu, Hazel A. Fernando, Charles E. Mordaunt, Jordan M. Hughey, John D. Eicher, Lara Robinson, Nicholas Bowker, Laurence Howe, Jimmy Liu, Adrian Cortes, Paul Wilson, Usha Gungabissoon, Victoria S. Benson, Anthony Nash, Gareth Young, Laura Addis, Chun-Fang Xu, Caleb Webber, Jonathan Davitte, M. Zameel Cader
Publish date:
28 May 2026
Journal:
Nature Communications
PubMed ID:
42209495

Abstract

Pain-related conditions are the leading cause of disability worldwide. Existing GWAS for chronic pain have mainly focused on individual pain-related disorders, which may not optimally capture the phenotype. Here, we define chronic pain based on prescription analgesic use ( ≥ 90 days) in two large biobanks (UK Biobank and FinnGen). GWAS meta-analyses of 11 prescription-based pain phenotypes identify 140 associations with chronic pain, including 78 novel (e.g. ARPP21, CNTNAP2) and 62 previously reported (e.g. SLC39A8, DCC, TRPM8) associations. Integrating these genetic associations with functional data including transcriptome-wide association studies, cell-type and pathway enrichment, and gene enrichment in mouse phenotypes identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling. Our study showcases how the use of prescription data to identify and characterize pain can provide insights into pain genetics and its underlying biology.

Related projects

Overall success rates for bringing novel medicines to patients are low. Reasons for failure in drug discovery and clinical development are many and complex, including…

Institution:
GlaxoSmithKline, USA, United States of America

All projects